WO2002056868A2 - Method for treating stress or tension - Google Patents
Method for treating stress or tension Download PDFInfo
- Publication number
- WO2002056868A2 WO2002056868A2 PCT/FI2002/000047 FI0200047W WO02056868A2 WO 2002056868 A2 WO2002056868 A2 WO 2002056868A2 FI 0200047 W FI0200047 W FI 0200047W WO 02056868 A2 WO02056868 A2 WO 02056868A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tension
- disorder
- anxiety disorder
- stress
- mammal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Definitions
- the present invention relates in general to a method for treating stress and/or tension in a mammal. More particularly, the invention relates to a method for treating stress and/or tension in a mammal by administering to the mammal an effective amount of l,7,7-trimethylbicyclo[2.2.1]heptane derivative of Formula I
- R is hydrogen or methyl, or a pharmaceutically acceptable salt thereof.
- the active ingredients of this invention (lR,2S,4R)-(-)- 2-phenyl 2- (dimethylaminoethoxy)-l,7J-trimethyl-bicyclo[2.2.1]heptane, known as deramciclane, and (lR,2S,4R)-(-)- 2-phenyl-2-(methylaminoethoxy)-lJJ-trimethyl- bicyclo[2.2.1]heptane, known as N-desmethylderamciclane, and their pharmaceutically acceptable acid addition salts with inorganic and organic acids generally used for the purpose, fall within the disclosures of U.S. Patent No. 4,342,762 and International Patent Application No. WO 98/17230, respectively, which are both incorporated herein by reference.
- an object of the present invention is a method for treating stress and/or tension in a mammal by administering to the mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
- stress is either an acute or chronic condition associated with a variety of types of symptoms, such as anxiety, nervousness, inner tension, insomnia, concentration difficulties, memory impairment, muscle tension and palpitation.
- tension is either an acute or chronic condition associated with either muscular tension (associated with symptoms like twitchings, stiffness, myoclonic jerks, grinding of teeth, unsteady voice or increased muscular tone) or other tension (associated with symptoms like feelings of tensions, fatigability, startle response, moving to tears easily, trembling, feelings of restlessness or inability to relax) or both.
- muscular tension associated with symptoms like twitchings, stiffness, myoclonic jerks, grinding of teeth, unsteady voice or increased muscular tone
- other tension associated with symptoms like feelings of tensions, fatigability, startle response, moving to tears easily, trembling, feelings of restlessness or inability to relax
- Stress and tension may also be associated with an affective disorder, such as depression or with an anxiety disorder, such as Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Panic Disorder (PD), Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD) or agoraphobia.
- GAD Generalized Anxiety Disorder
- SAD Social Anxiety Disorder
- PD Panic Disorder
- OCD Obsessive Compulsive Disorder
- Post-Traumatic Stress Disorder PTSD
- agoraphobia aphobia
- treatment means treatment in order to cure or alleviate the disease or its symptoms, and to treatment in order to prevent the development or the exacerbation of the disease or its symptoms.
- Pharmaceutically acceptable salts of the compound of Formula (I) can be formed with inorganic acids, e.g. hydrohalogenic acid such as hydrochloric acid or hydrobromic acid, sulfuric acid, phosphoric acid or nitric acid, or organic acids e.g., tartaric acid, succinic acid, malic acid, maleic acid, fumaric acid, citric acid, or lactic acid. Salt with fumaric acid is preferred.
- hydrohalogenic acid such as hydrochloric acid or hydrobromic acid
- sulfuric acid phosphoric acid or nitric acid
- organic acids e.g., tartaric acid, succinic acid, malic acid, maleic acid, fumaric acid, citric acid, or lactic acid. Salt with fumaric acid is preferred.
- compositions containing a compound of Formula (I) or a pharmaceutically acceptable salt thereof as the active ingredient include the usual oral dosage forms, such as tablets, capsules, and liquid preparations.
- the active ingredient can be mixed with suitable pharmaceutically acceptable excipients, such as starch, lactose, sucrose and magnesium stearate, in accordance with conventional pharmaceutical practice.
- the precise amount of the drug to be administered to a mammal for the treatment of stress is dependent on numerous factors known to one skilled in the art, such as the compound to be administered, the general condition of the patient, the condition to be treated etc.
- the usual recommended oral daily dose of deramciclane would be about 5-150 mg/day, or about 10-60 mg/day, or about 30-60 mg/day, or about 30 mg/day.
- VAS Visual Analogue Scale
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/466,716 US20040082665A1 (en) | 2001-01-22 | 2002-01-22 | Method for treating stress or tension |
AU2002229794A AU2002229794A1 (en) | 2001-01-22 | 2002-01-22 | Method for treating stress or tension |
EP02710903A EP1353656A2 (en) | 2001-01-22 | 2002-01-22 | Method for treating stress or tension |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76532901A | 2001-01-22 | 2001-01-22 | |
US09/765,329 | 2001-01-22 | ||
US32728701P | 2001-10-09 | 2001-10-09 | |
US60/327,287 | 2001-10-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002056868A2 true WO2002056868A2 (en) | 2002-07-25 |
WO2002056868A3 WO2002056868A3 (en) | 2002-12-12 |
Family
ID=26985798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FI2002/000047 WO2002056868A2 (en) | 2001-01-22 | 2002-01-22 | Method for treating stress or tension |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1353656A2 (en) |
AU (1) | AU2002229794A1 (en) |
WO (1) | WO2002056868A2 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998017230A2 (en) * | 1996-10-17 | 1998-04-30 | EGIS Gyógyszergyár Rt. | New 1,7,7-trimethyl-bicyclo[2.2.1]heptane derivatives |
-
2002
- 2002-01-22 AU AU2002229794A patent/AU2002229794A1/en not_active Abandoned
- 2002-01-22 EP EP02710903A patent/EP1353656A2/en not_active Withdrawn
- 2002-01-22 WO PCT/FI2002/000047 patent/WO2002056868A2/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998017230A2 (en) * | 1996-10-17 | 1998-04-30 | EGIS Gyógyszergyár Rt. | New 1,7,7-trimethyl-bicyclo[2.2.1]heptane derivatives |
Also Published As
Publication number | Publication date |
---|---|
WO2002056868A3 (en) | 2002-12-12 |
EP1353656A2 (en) | 2003-10-22 |
AU2002229794A1 (en) | 2002-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101125462B1 (en) | Pharmaceutical formulations of modafinil | |
JPH0635382B2 (en) | Uses of fluoxetine as an anxiolytic | |
US6335371B1 (en) | Method for inducing cognition enhancement | |
AU780379B2 (en) | Orally distintegrating composition comprising mirtazapine | |
NO309965B1 (en) | Oral pharmaceutical anti-cough preparation | |
US20190224208A1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
KR100692235B1 (en) | New use of angiotensin ii antagonists | |
US6335372B1 (en) | Treatment of obsessive compulsive disorder | |
US20040082665A1 (en) | Method for treating stress or tension | |
EP1353656A2 (en) | Method for treating stress or tension | |
WO2002056869A2 (en) | Method for treating sexual disorders | |
US6589996B2 (en) | Treatment of disorders relating to the serotonergic system | |
WO2002043727A1 (en) | Treatment of psychiatric disorders with trimethyl-bicyclo[2.2.1]heptane derivatives | |
WO2002056870A2 (en) | Method for treating sleep disorders | |
JP2022540854A (en) | Combination of ibuprofen and tramadol for pain relief | |
US5834497A (en) | Use of felodipine to treat cerebral dysfunction due to solvent exposure | |
JP2005527634A (en) | How to use milnacipran for the treatment of tension headache | |
WO2004037238A1 (en) | New uses of deramciclane | |
KR20220110259A (en) | A combination of mirtazapine and tizanidine for use in pain disorders | |
WO2002043724A1 (en) | Combination therapy for treatment of serotonergic disorders | |
OA16802A (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10466716 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002710903 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002710903 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002710903 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |